olivLaw · US equity research
Summit Therapeutics Inc. SMMT
Pharmaceutical Preparations · SIC 2834 · Vertical: Pharmaceutical Preparations (SIC 2834)
Summit Therapeutics is a biopharmaceutical company developing ivonescimab, a bispecific PD-1 and VEGF antibody in Phase III trials for non-small cell lung cancer and colorectal cancer. The company has filed for FDA approval with a decision date of November 2026, and its net loss of 1079.6 million USD in 2025 shows the business is still in development with no significant commercial revenue.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 04 Nov 2026, Summit Therapeutics Inc. (SMMT) stock was 16.17 USD (+2.34% on the day), with market capitalisation 12.9 bn USD, dividend yield 0.00%, beta 1.68, 52-week range 12.43–26.38 USD. Latest reported quarter (Q3 2026): net income of -208.4 m USD, diluted EPS -0.26 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 52.0
- neutral
- Bollinger (20, 2)
- 14.20 – 17.36
- in the upper half of the band · %B 0.62 · band width 20.0%
- SMA 50 / 200
- 16.21 / 16.15
- mixed trend
- MACD (12, 26, 9)
- -0.14 / -0.18
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −6.4% | −1.1% | −5.3 pp | — |
| 3 months | +19.5% | −0.5% | +20.0 pp | — |
| 6 months | −9.4% | +4.4% | −13.8 pp | — |
| Year to date | −7.5% | +12.3% | −19.9 pp | — |
| 1 year | −7.5% | +13.5% | −21.1 pp | +8.9% |
| 3 years | +704.5% | +76.4% | +628.1 pp | +15.7% |
| 5 years | +186.7% | +63.7% | +123.0 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q3 2026 · 30 Sept 2026
Quarterly statements · USD
| Fiscal year | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | — | — | — | — | — | — | — |
| Research & development | — | 51.3 m | 208.0 m | 131.1 m | — | 132.6 m | 157.7 m | 169.1 m |
| Operating income | -65.6 m | — | — | — | — | — | — | — |
| Interest expense | 9.0 k | 0 | 0 | 0 | 0 | — | — | — |
| Net income | -61.2 m | -62.9 m | -565.7 m | -231.8 m | -219.2 m | -189.4 m | -215.7 m | -208.4 m |
| Diluted EPS | -0.08 ≈ | -0.09 | -0.76 | -0.31 | -0.29 ≈ | -0.24 | -0.28 | -0.26 |
| Operating cash flow | -48.7 m | -61.2 m | -66.7 m ≈ | -93.1 m ≈ | -101.9 m | -122.3 m | -141.1 m ≈ | -159.8 m ≈ |
| Capex | 14.0 k | 422.0 k | 0 ≈ | 71.0 k ≈ | 164.0 k | 245.0 k | 909.0 k ≈ | 396.0 k ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | ⚠ 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 25.4 m | 57.1 m | 860.0 k | 1.8 m | 705.0 k | 0 | 0 | unavailable |
| Revenue YoY | +1,003.3% | — | −98.5% | +110.3% | −61.0% | −100.0% | unavailable | unavailable |
| Net income | -20.2 m | 10.9 m | -52.7 m | -88.6 m | -78.8 m | -614.9 m | -221.3 m | -1.1 bn |
| Net income YoY | unavailable | — | −584.8% | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | -0.31 | 0.63 | -0.76 | -0.67 | -0.41 | -0.99 | -0.31 | -1.44 |
| Diluted EPS YoY | unavailable | — | −220.6% | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | -79.3% | 19.0% | -6,127.6% | -4,897.8% | -11,174.8% | unavailable | unavailable | unavailable |
| Free cash flow | -14.9 m | -35.3 m | -48.5 m | -72.9 m | -42.2 m | -76.9 m | -142.2 m | -323.6 m |
The series breaks before 2019: earlier years come from the original reports of the issuer of that time, later years from a subsequent filing that restated the perimeter (a separation, discontinued operations). The year-on-year change across the break is not shown.
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 225.3 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 658.9 m USD
- Total assets
- 751.2 m USD
- Debt / equity
- unavailable
- Current ratio
- 9.87x
- ROE
- -206.1%
- ROA
- -181.9%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 860.0 k | 1.8 m | 705.0 k | 0 | 0 | — | SEC (XBRL)· 24 Feb 2025verified |
| Research & development | 53.3 m | 85.4 m | 52.0 m | 59.5 m | — | — | SEC (XBRL)· 20 Feb 2024verified |
| Operating income | -53.2 m | -86.2 m | -72.1 m | -609.7 m | -226.0 m | — | SEC (XBRL)· 24 Feb 2025verified |
| Interest expense | 255.0 k | 242.0 k | 4.4 m | 16.5 m | 8.7 m | 0 | SEC (XBRL)· 23 Feb 2026verified |
| Pre-tax income | -52.9 m | -88.6 m | -78.8 m | -614.9 m | -221.3 m | -1.1 bn | SEC (XBRL)· 23 Feb 2026verified |
| Income tax | -213.0 k | 0 | — | 0 | 0 | 0 | SEC (XBRL)· 23 Feb 2026verified |
| Net income | -52.7 m | -88.6 m | -78.8 m | -614.9 m | -221.3 m | -1.1 bn | SEC (XBRL)· 23 Feb 2026verified |
| Diluted EPS | -0.76 | -0.67 | -0.41 | -0.99 | -0.31 | -1.44 | SEC (XBRL)· 23 Feb 2026verified |
| Weighted average diluted shares | 69.5 m | 131.7 m | 193.3 m | 619.6 m | 718.5 m | 747.7 m | SEC (XBRL)· 23 Feb 2026verified |
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 66.4 m | 71.8 m | 348.6 m | 71.4 m | 104.9 m | 225.3 m | SEC (XBRL)· 23 Feb 2026verified |
| Receivables | 331.0 k | 1.5 m | 349.0 k | 0 | — | — | SEC (XBRL)· 20 Feb 2024verified |
| Current assets | 87.7 m | 97.3 m | 656.7 m | 189.7 m | 423.8 m | 720.3 m | SEC (XBRL)· 23 Feb 2026verified |
| Property, plant & equipment, net | 725.0 k | 694.0 k | 906.0 k | 204.0 k | 254.0 k | 1.1 m | SEC (XBRL)· 23 Feb 2026verified |
| Goodwill | 2.0 m | 2.0 m | 1.8 m | 1.9 m | 1.9 m | 2.0 m | SEC (XBRL)· 23 Feb 2026verified |
| Intangibles (excl. goodwill) | 11.5 m | 10.4 m | 0 | 0 | 0 | — | SEC (XBRL)· 24 Feb 2025verified |
| Total assets | 102.5 m | 113.4 m | 664.2 m | 202.9 m | 435.6 m | 751.2 m | SEC (XBRL)· 23 Feb 2026verified |
| Accounts payable | 6.1 m | 4.4 m | 355.0 k | 2.7 m | 4.6 m | 20.3 m | SEC (XBRL)· 23 Feb 2026verified |
| Current liabilities | 19.9 m | 25.6 m | 38.8 m | 20.4 m | 41.7 m | 73.0 m | SEC (XBRL)· 23 Feb 2026verified |
| Total liabilities | 23.0 m | 30.1 m | 537.5 m | 125.3 m | 46.8 m | 92.3 m | SEC (XBRL)· 23 Feb 2026verified |
| Equity | 79.5 m † | 83.3 m † | 126.7 m † | 77.7 m † | 388.7 m † | 658.9 m † | SEC (XBRL)· 23 Feb 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -48.1 m | -72.6 m | -41.6 m | -76.8 m | -142.1 m | -322.9 m | SEC (XBRL)· 23 Feb 2026verified |
| Capex | 421.0 k | 306.0 k | 624.0 k | 128.0 k | 139.0 k | 657.0 k | SEC (XBRL)· 23 Feb 2026verified |
| Free cash flow | -48.5 m ≈ | -72.9 m ≈ | -42.2 m ≈ | -76.9 m ≈ | -142.2 m ≈ | -323.6 m ≈ | SEC (XBRL)· 23 Feb 2026derived |
| Investing cash flow | -421.0 k | -306.0 k | -624.0 k | -587.8 m | -205.3 m | -174.3 m | SEC (XBRL)· 23 Feb 2026verified |
| Financing cash flow | 50.6 m | 77.9 m | 620.2 m | 86.5 m | 381.2 m | 617.5 m | SEC (XBRL)· 23 Feb 2026verified |
| Dividends paid | 0 | — | — | — | — | — | SEC (XBRL)· 31 Mar 2021verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 2 of at least 6
- score weight coverage: 12.5% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 12.9 bn USD
Key indicators
Coverage and freshness
Score by group
13% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the base of the ratio is not positive
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 2 of at least 6; score weight coverage: 12.5% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | unavailable | unavailable | — |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 6.0x | 100 (on a fixed band) | 33% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -4.1% | 0 (on a fixed band) | 67% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial100/100 · 1/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality· partialunavailable · 0/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Summit Therapeutics Inc. (SMMT). Latest full fiscal year: 2024; data up to 2026-09-30.
Figures computed from the financial statements: revenue 0 USD in 2024; ROE -220.0%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 2 of at least 6; score weight coverage: 12.5% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 6.0x
What contradicts it
- FCF yield: -4.1%
Not assessed (insufficient data or a ratio without meaning): ROIC, Net margin, FCF conversion, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, Interest coverage, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Pharmaceutical Preparations (SIC 2834) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| LLYEli Lilly And Company | 1,334.0 bn | 46.0 | 86.1% | 31.9% | +44.7% | +32% / +140% |
| JNJJohnson & Johnson | 665.2 bn | 41.9 | 20.0% | 16.2% | +6.0% | +34% / +79% |
| ONCBeone Medicines Ltd. | 558.4 bn | 869.9 | 14.7% | 10.7% | +40.2% | +11% / +102% |
| ABBVAbbVie Inc. | 521.1 bn | 50.7 | — | 15.7% | +8.6% | +29% / +107% |
| MRKMerck & Co., Inc. | 370.7 bn | 154.7 | 5.1% | 3.6% | +1.3% | +43% / +47% |
| ABTAbbott Laboratories | 200.1 bn | 43.0 | 9.2% | 9.7% | +5.7% | −10% / +11% |
| PFEPfizer Inc | 175.5 bn | 43.9 | 4.4% | 6.3% | −1.6% | +20% / +1% |
| VRTXVertex Pharmaceuticals Inc | 139.2 bn | 35.3 | 20.8% | 30.7% | +8.9% | +27% / +55% |
| BMYBristol-Myers Squibb Company | 131.2 bn | 14.2 | 44.1% | 18.5% | −0.2% | +30% / +30% |
| TEVATeva Pharmaceutical Industries Limited | 48.8 bn | 97.4 | 6.6% | 3.6% | +4.3% | +56% / +326% |
| ZTSZoetis Inc. | 36.9 bn | 14.7 | 64.4% | 27.5% | +2.3% | −30% / −50% |
| ROIVRoivant Sciences Ltd. | 27.6 bn | — | -6.2% | -3,535.0% | −71.6% | +84% / +300% |
| RPRXRoyalty Pharma plc | 26.2 bn | 47.7 | 6.9% | 25.7% | +5.1% | +69% / +150% |
| UTHRUnited Therapeutics Corporation | 25.9 bn | 23.0 | 19.1% | 38.6% | +10.6% | +25% / +154% |
| INSMInsmed Inc | 24.1 bn | — | -72.5% | -39.9% | +66.7% | −47% / +340% |
| VTRSViatris Inc. | 22.1 bn | — | -23.6% | -23.9% | −3.0% | +80% / +109% |
| ALNYAlnylam Pharmaceuticals, Inc. | 21.6 bn | 8.1 | 126.6% | 52.8% | +65.2% | −64% / −4% |
| ORKAOruka Therapeutics, Inc. | 6.7 bn | — | -18.2% | — | unavailable | +237% / +364% |
| HRMYHarmony Biosciences Holdings, Inc. | 2.0 bn | 11.4 | 18.7% | 18.1% | +21.5% | −2% / +18% |
| OMEROmeros Corp | 1.3 bn | 10.5 | — | — | −34.0% | +88% / +730% |
| VSTMVerastem, Inc. | 892.0 m | — | -471.2% | -231.6% | +209.1% | −7% / +43% |
| COLLCollegium Pharmaceutical, Inc. | 770.6 m | 19.1 | 17.6% | 5.9% | +23.6% | −49% / −8% |
| IBOImpact BioMedical, INC. | 442.1 m | 560.3 | 371.3% | 2,254.3% | unavailable | −27% / unavailable |
| KMDAKamada Ltd | 428.0 m | 21.2 | 7.6% | 11.2% | +12.1% | +11% / +57% |
| EPRXEupraxia Pharmaceuticals Inc. | 240.9 m | — | -66.8% | — | unavailable | +9% / unavailable |
1- and 3-year price returns: for SMMT from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 23 Jul 2026; since then the company filed 8-K (04 Nov 2026 · results), 10-Q (04 Nov 2026).
In brief
Summit Therapeutics is a biopharmaceutical company developing ivonescimab, a bispecific PD-1 and VEGF antibody in Phase III trials for non-small cell lung cancer and colorectal cancer. The company has filed for FDA approval with a decision date of November 2026, and its net loss of 1079.6 million USD in 2025 shows the business is still in development with no significant commercial revenue.
SWOT
Strengths
- The company has a Phase III program with positive progression-free survival results and a clear focus on one product.
- Exclusive rights across several major territories provide a framework for commercialization without sharing the market with the licensor.
- The HARMONi-6 results from China are supported by a favorable statistical analysis of overall survival.
Weaknesses
- The company has no significant commercial revenue and depends on external financing.
- Dependence on a single product means clinical or regulatory setbacks would have a major impact.
- The HARMONi study did not reach statistical significance for overall survival, which limits the case for approval.
Opportunities
- A favorable FDA decision could open access to the US market and support other filings.
- Expanding the program into other tumors and collaborations could diversify risk.
- Updated survival data in the western population could strengthen the argument for approval.
Threats
- An FDA rejection or requests for more data could delay commercialization.
- Competition from anti-PD-1 therapies and other bispecifics could reduce potential market share.
- Volatile market conditions and high development costs could limit access to capital.
Risks
- Regulatory decisionhigh
The application for HARMONi has no decision yet, and the FDA said a statistically significant overall survival benefit is needed.
- Funding needhigh
Large net losses and contingent payments to Akeso could require new financing, with dilution effects.
- Single-product dependencehigh
The whole program depends on ivonescimab, so a clinical failure could seriously affect the company.
- Safety profilemedium
Grade 3 or higher adverse events and bleeding could limit use and influence the regulatory decision.
- Geopolitical risksmedium
Conflicts in Europe and the Middle East could affect trial enrollment and drug supply.
Investment thesis
What would need to be true (bull case)
- If the FDA approves ivonescimab, the company could become the first to commercialize a PD-1/VEGF bispecific in the United States.
- The HARMONi-6 results and updated survival data could support differentiation from anti-PD-1 therapies.
- Collaborations with other companies could extend use of the product to several tumor types.
What would break the thesis
- If the FDA rejects the application or requests more studies, commercialization could be delayed by years.
- Large net losses and payment obligations to the partner could force costly financing.
- If overall survival benefit fails to hold in western studies, the commercial case could be weak.
What to watch
- FDA decision on ivonescimab application in EGFR-mutated NSCLCNovember 2026
- HARMONi-3 squamous cohort interim analysis results2026
- PFS analysis for HARMONi-3 non-squamous cohortFirst half of 2027
- Revenue and net loss in the next annual reportNext 10-K
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 23 Jul 2026; since then the company filed 8-K (04 Nov 2026 · results), 10-Q (04 Nov 2026).
The business
Summit Therapeutics Inc. is a biopharmaceutical company that discovers, develops and commercializes oncology therapies, with its lead product ivonescimab, a bispecific antibody that the company says could combine immunotherapy effects with VEGF inhibition 1. It in-licensed rights from Akeso covering the United States, Canada, Europe, Japan, Latin America, the Middle East and Africa 1. Activity so far is mostly clinical development, and the company has no significant commercial revenue.
In May 2025 the HARMONi Phase III study showed a statistically significant progression-free survival improvement with a hazard ratio of 0.52, though overall survival did not reach statistical significance 1. The FDA accepted the biologics license application in January 2026, with a decision date of November 14, 2026 1. A Chinese study run by partner Akeso, HARMONi-6, later reported a statistically significant overall survival improvement over an anti-PD-(L)1 regimen 3.
Beyond the lead therapy, the company has expanded through clinical collaborations, including one with Arcus Biosciences in renal cell carcinoma and one with Revolution Medicines combining ivonescimab with RAS inhibitors 3. The business depends heavily on one product, and net losses remain substantial 1.
Segments
Ivonescimab in non-small cell lung cancer
The most advanced indication is HARMONi, for EGFR-mutated NSCLC after TKI therapy, for which the FDA accepted the application 1. HARMONi-3 and HARMONi-7 continue in first-line treatment.
Ivonescimab in colorectal and other tumors
The company is developing HARMONi-GI3 for first-line unresectable metastatic colorectal cancer and has signaled possible Phase III studies in other tumor types 3. These programs are early or still enrolling.
Market context
Trends
- Bispecific PD-1/VEGF antibodiestailwind
Interest in combining PD-1 blockade with VEGF inhibition in one molecule could open a new class of treatments if clinical results hold 1.
- Overall survival requirementsheadwind
The FDA indicated that a statistically significant overall survival benefit is needed, which the HARMONi study did not reach 1.
- Unstable economic and geopolitical conditionsheadwind
Geopolitical conflicts and volatile capital markets could make financing harder and affect clinical trials 1.
- Need for additional fundingmixed
Payments to Akeso and development costs require new financing through equity, debt or partnerships, which could dilute existing shareholders 1.
Competitive position
Competition includes anti-PD-1 and anti-PD-L1 therapies used in first-line treatment, such as pembrolizumab, as well as other anti-VEGF or bispecific agents in development. The company acknowledges it must compete with approved therapies, which requires strong comparative data 13.
Over the longer term, the competitive edge could depend on head-to-head results and on a safety profile the company considers acceptable and manageable 2.
- Merck (pembrolizumab)MRK
Pembrolizumab is the comparator in the HARMONi-3 first-line NSCLC study.
- Akeso (ivonescimab in China)
The partner that holds ivonescimab rights in China and other territories.
- Arcus Biosciences
Collaboration partner for a combination with a HIF-2α inhibitor in renal cell carcinoma.
- Revolution Medicines
Collaboration partner for combinations with RAS inhibitors in solid tumors.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Russian diplomat assesses potential Russia-US-China summit as positive impetusTASS (RU, EN) · 05 Nov 2026 · EN
- Lee welcomes East Timor President Horta's visit to S. Korea ahead of summitYonhap News (KR, EN) · 05 Nov 2026 · EN
- Spain: Madrid hosts 30th Ibero-American Summit with 22-nation blocEuronews — News (EN) · 04 Nov 2026 · EN
- (News Focus) Democratic control of Congress could complicate S. Korea's nuclear submarines, Trump-Kim summit prospects: expertsYonhap News (KR, EN) · 04 Nov 2026 · EN
- China's open-source AI push gains momentum at WIC Wuzhen SummitCGTN — World · 04 Nov 2026 · EN
- Upcoming COP31 summit crucial to turning climate ambitions into global action, ECB chief saysAnadolu Agency (TR, EN) · 04 Nov 2026 · EN
- After the Seoul summit: Institutionalizing the Turkish-South Korean partnershipAnadolu Agency (TR, EN) · 04 Nov 2026 · EN
- China Confirms Talks on Potential Trump-Putin-Xi Summit After Weeks of SilenceKyiv Post · 04 Nov 2026 · EN
- China's Foreign Ministry confirms talks with US and Russia on three-leader summit – BloombergUkrainska Pravda (UA, EN) · 04 Nov 2026 · EN
- Ukraine, EU enlargement and energy to top agenda of Visegrad Four summitUkrinform (UA, EN) · 04 Nov 2026 · EN
- Xi's special representative Han Zheng to attend COP31 leaders' summitCGTN — World · 04 Nov 2026 · EN
- China in contact with relevant parties on China-Russia-US summitCGTN — World · 04 Nov 2026 · EN
- Chinese vice president to attend UN climate summit in TürkiyeAnadolu Agency (TR, EN) · 04 Nov 2026 · EN
- Follow one-China principle for APEC summit, China tells TaiwanAnadolu Agency (TR, EN) · 04 Nov 2026 · EN
- North Korea pours cold water on Kim-Trump meeting as APEC summit loomsThe Japan Times · 04 Nov 2026 · EN
- Live: Two Sigma, Top Money Managers Speak at HK Investment Summit Day 2Bloomberg Markets · 04 Nov 2026 · EN
- King Charles addresses summit as demands for slavery apology growThe Guardian World · 03 Nov 2026 · EN
- Ankara summit was a turning point for OTSDaily Sabah — Economy (TR, EN) · 03 Nov 2026 · EN
- APEC host China to keep cars off street, close schools during Shenzhen summitNikkei Asia · 03 Nov 2026 · EN
- Kobakhidze on Defensive During Euronews Enlargement Summit Interview in BrusselsCivil.ge (GE, EN) · 03 Nov 2026 · EN
SEC filings
- Current report04 Nov 2026Other events · Financial statements and exhibits
- Quarterly report04 Nov 2026
- Current report04 Nov 2026Results of operations · Amendments to articles or bylaws · Shareholder vote · Financial statements and exhibits
- Proxy statement19 Oct 2026
- Current report29 Sept 2026Material agreement · Item 3.02 · Amendments to articles or bylaws · Other events · Financial statements and exhibits
- Current report15 Sept 2026Other events · Financial statements and exhibits
- Current report14 Sept 2026Other events · Financial statements and exhibits
- Current report03 Sept 2026Other events · Financial statements and exhibits
- Current report26 Aug 2026Other events · Financial statements and exhibits
- Current report05 Aug 2026Other events · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Summit Therapeutics Inc. · 23 Feb 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Summit Therapeutics Inc. · 23 Jul 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Summit Therapeutics Inc. · 23 Jul 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.